Search Results for: New Preclinical Studies Reinforce the
Articles
New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine’s Proprietary Delivery Platform April 23, 2018
Immunovaccine Inc. recently announced that it presented new research on its T-cell activating platform at the American Association for Cancer...Ocean Biomedical Announces Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody December 5, 2023
Ocean Biomedical, Inc. recently announced its Scientific Co-founder, Jack A. Elias, MD, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of….
Albireo Pharma Announces New Phase 3 Data That Shows Durable Response to Odevixibat in a Rare Pediatric Liver Disease November 18, 2020
Albireo Pharma, Inc. recently announced new data in progressive familial intrahepatic cholestasis (PFIC) confirming statistically significant reductions in serum bile...Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans November 15, 2018
Aptinyx Inc. recently announced that exploratory clinical studies of its novel NMDA receptor (NMDAr) modulator, NYX-2925, provide the first evidence...GW Pharmaceuticals Announces New Positive Phase III Data December 12, 2016
GW Pharmaceuticals plc recently announced additional positive Epidiolex (cannabidiol or CBD) Phase III data in poster presentations at the 70th...Itamar Medical & Roche Sign Agreement For EndoPAT Devices in Preclinical Drug Development January 3, 2011
Itamar Medical, a leader in non-invasive vascular health diagnostics, recently announced that an agreement has been signed with Roche by...THERAPEUTIC FOCUS - Perspectives on Sigma-2 Modulation as a Therapeutic Modality for Slowing Age-Related Degenerative Disease March 28, 2024
Anthony Caggiano, MD, PhD, believes there is evidence the sigma-2 receptor acts as a regulator of cellular processes, such as autophagy and protein trafficking, which are impaired in age-related degenerative diseases.
CLINICAL TRIALS - The Power of AI in Overcoming Patient Diversity Challenges January 26, 2024
Isaac Bentwich, PhD, explores why patient diversity is such a challenge for clinical trials, where that pain is often felt the most, some of the regulatory, technological, and industry changes already underway to solve the clinical trial gap, and where AI changes the future of patient diversity.
LIPOSOMAL PEPTIDE THERAPEUTICS - Revolutionizing Oncology: Unleashing Innovative Strategies to Tackle Challenging, High-Value Drug Targets December 4, 2023
Natalia Zisman, Krishna Allamneni, PhD, and Stacy W. Blain, PhD, explain how targeting downstream signaling proteins offers a promising approach to effectively mitigate the emergence of drug resistance that precision oncology therapies leave behind.
Enterome Announces First Patient Dosed in Phase 1/2 Trial With Third OncoMimics Immunotherapy in Metastatic Colorectal Cancer June 30, 2023
Enterome recently announced the first patient was dosed in the Phase 1/2 AUDREY trial evaluating EO4010, the company’s third OncoMimics candidate, for the treatment of patients with….
EXECUTIVE INTERVIEW - Purple Biotech Ltd.: Developing First-In-Class Oncology Therapies March 1, 2023
Gil Efron, Chief Executive Officer of Purple Biotech, discusses the company’s focus on identifying and developing promising molecules that may offer first-in-class approaches to treating devastating cancers with large unmet medical needs.
BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer February 14, 2023
BioXcel Therapeutics, Inc. recently announced full data from its Phase 2a trial of BXCL701, the company’s investigational, oral innate immune activator, in combination with….
Avidity Biosciences Granted FDA Fast Track Designation for the Treatment of Facioscapulohumeral Muscular Dystrophy January 18, 2023
Avidity Biosciences, Inc. recently announced the US FDA has granted Fast Track designation to AOC 1020 for the treatment of...Avidity Announces Positive AOC 1001 Phase 1/2 MARINA Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics December 14, 2022
Avidity Biosciences, Inc. recently announced positive AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial demonstrating the first-ever….
US Patent Issued to HCW Biologics for Foundational Platform Technology August 3, 2022
HCW Biologics Inc. was granted US Patent No. 11,401,324, which contains claims for immunotherapeutic compounds comprised of a single-chain chimeric...Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 With In-Process Vaccine Candidate January 31, 2022
Celsion Corporation recently announced it has engaged BIOQUAL, Inc., a preclinical testing contract research organization, to conduct a non-human primate (NHP) challenge study with Celsion’s DNA-based approach for….
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected With Influenza Virus December 1, 2021
SAB Biotherapeutics recently announced that SAB-176, its investigational therapeutic for the treatment of seasonal influenza, achieved statistically significant (p = 0.026) reductions in viral load and….
Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy & Powerful Potential of Antigen-Independent Tumor Targeting October 26, 2021
Cybrexa Therapeutics recently announced favorable early Phase 1 data for its lead therapeutic candidate, CBX-12 (alphalex-exatecan). The initial data show robust….
Landos Biopharma Announces First Patient Dosed in Global Phase 2 Clinical Trial August 22, 2019
Landos Biopharma, Inc. recently announced dosing of the first patient in a Phase 2 study evaluating the safety and efficacy...Regentys, Cook Biotech to Collaborate in Developing, Delivering Unique Ulcerative Colitis Treatment February 19, 2018
Regentys recently announced it will partner with Cook Biotech Inc. to develop a novel treatment for ulcerative colitis. Under the...
